Publication Activity (10 Years)
Years Active: 2017-2024
Publications (10 Years): 59
Publications (10 Years): 59
Publications
- Hiroki Ishihara, Toshio TakagiEditorial Comment on Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy. International journal of urology : official journal of the Japanese Urological Association 31 (5) (2024)
- Maki Yoshino, Hiroki Ishihara, Yuki Nemoto, Shinsuke Mizoguchi, Takashi Ikeda, Takayuki Nakayama, Hironori Fukuda, Kazuhiko Yoshida, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Tsunenori Kondo, Toshio Takagi
- Hiroki Ishihara, Kenji Omae, Yuki Nemoto, Ryo Ishiyama, Hidekazu Tachibana, Koichi Nishimura, Takashi Ikeda, Yuki Kobari, Hironori Fukuda, Kazuhiko Yoshida, Hiroaki Shimmura, Yasunobu Hashimoto, Junpei Iizuka, Tsunenori Kondo, Toshio TakagiFirst-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data. International journal of clinical oncology 29 (4) (2024)
- Hiroki Ishihara, Nemoto Yuki, Ryo Ishiyama, Takashi Ikeda, Yuki Kobari, Hironori Fukuda, Kazuhiko Yoshida, Hiroaki Shimmura, Yasunobu Hashimoto, Junpei Iizuka, Tsunenori Kondo, Toshio Takagi
- Hiroki Ishihara, Toshio TakagiEditorial Comment on Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy. International journal of urology : official journal of the Japanese Urological Association 31 (5) (2024)
- Maki Yoshino, Hiroki Ishihara, Yuki Nemoto, Shinsuke Mizoguchi, Takashi Ikeda, Takayuki Nakayama, Hironori Fukuda, Kazuhiko Yoshida, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Tsunenori Kondo, Toshio Takagi
- Hiroki Ishihara, Toshio TakagiEditorial Comment on Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy. International journal of urology : official journal of the Japanese Urological Association 31 (5) (2024)
- Hiroki Ishihara, Kenji Omae, Yuki Nemoto, Ryo Ishiyama, Hidekazu Tachibana, Koichi Nishimura, Takashi Ikeda, Yuki Kobari, Hironori Fukuda, Kazuhiko Yoshida, Hiroaki Shimmura, Yasunobu Hashimoto, Junpei Iizuka, Tsunenori Kondo, Toshio TakagiFirst-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data. International journal of clinical oncology (2024)
- Hiroki Ishihara, Nemoto Yuki, Ryo Ishiyama, Takashi Ikeda, Yuki Kobari, Hironori Fukuda, Kazuhiko Yoshida, Hiroaki Shimmura, Yasunobu Hashimoto, Junpei Iizuka, Tsunenori Kondo, Toshio Takagi
- Hiroki Ishihara, Yuki Nemoto, Shinsuke Mizoguchi, Koichi Nishimura, Takashi Ikeda, Hironori Fukuda, Kazuhiko Yoshida, Hiroaki Shimmura, Yasunobu Hashimoto, Junpei Iizuka, Tsunenori Kondo, Toshio Takagi
- Hiroki Ishihara, Toshio TakagiEditorial Comment on Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy. International journal of urology : official journal of the Japanese Urological Association (2024)
- Hiroki Ishihara, Nemoto Yuki, Ryo Ishiyama, Takashi Ikeda, Yuki Kobari, Hironori Fukuda, Kazuhiko Yoshida, Hiroaki Shimmura, Yasunobu Hashimoto, Junpei Iizuka, Tsunenori Kondo, Toshio Takagi
- Hiroki Ishihara, Toshio TakagiEditorial Comment on Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy. International journal of urology : official journal of the Japanese Urological Association 31 (5) (2024)
- Hiroki Ishihara, Kenji Omae, Yuki Nemoto, Ryo Ishiyama, Hidekazu Tachibana, Koichi Nishimura, Takashi Ikeda, Yuki Kobari, Hironori Fukuda, Kazuhiko Yoshida, Hiroaki Shimmura, Yasunobu Hashimoto, Junpei Iizuka, Tsunenori Kondo, Toshio TakagiFirst-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data. International journal of clinical oncology 29 (4) (2024)
- Maki Yoshino, Hiroki Ishihara, Yuki Nemoto, Shinsuke Mizoguchi, Takashi Ikeda, Takayuki Nakayama, Hironori Fukuda, Kazuhiko Yoshida, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Tsunenori Kondo, Toshio Takagi
- Hiroki Ishihara, Nemoto Yuki, Ryo Ishiyama, Takashi Ikeda, Yuki Kobari, Hironori Fukuda, Kazuhiko Yoshida, Hiroaki Shimmura, Yasunobu Hashimoto, Junpei Iizuka, Tsunenori Kondo, Toshio Takagi
- Hiroki Ishihara, Yuki Nemoto, Kazutaka Nakamura, Hidekazu Tachibana, Takashi Ikeda, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Tsunenori Kondo, Toshio TakagiComparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study. Targeted oncology (2023)
- Kazuhiko Yoshida, Nao Oida, Tsunenori Kondo, Yuki Kobari, Hiroki Ishihara, Hironori Fukuda, Junpei Iizuka, Hirohito Kobayashi, Hideki Ishida, Toshio Takagi
- Hiroki Ishihara, Toshio TakagiEditorial Comment on Disease-free survival as a predictor of overall survival in localized renal cell carcinoma following initial nephrectomy: A retrospective analysis of Surveillance, Epidemiology and End Results-Medicare data. International journal of urology : official journal of the Japanese Urological Association 30 (3) (2023)
- Hiroki Ishihara, Toshio TakagiEditorial Comment on Disease-free survival as a predictor of overall survival in localized renal cell carcinoma following initial nephrectomy: A retrospective analysis of Surveillance, Epidemiology and End Results-Medicare data. International journal of urology : official journal of the Japanese Urological Association (2023)
- Hiroki Ishihara, Takashi Ikeda, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Yoji Nagashima, Tsunenori Kondo, Toshio Takagi
- Hiroki Ishihara, Yuki Nemoto, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Yasunobu Hashimoto, Tsunenori Kondo, Toshio Takagi
- Kazuhiko Yoshida, Nao Oida, Tsunenori Kondo, Yuki Kobari, Hiroki Ishihara, Hironori Fukuda, Junpei Iizuka, Hirohito Kobayashi, Hideki Ishida, Toshio Takagi
- Kazuhiko Yoshida, Nao Oida, Tsunenori Kondo, Yuki Kobari, Hiroki Ishihara, Hironori Fukuda, Junpei Iizuka, Hirohito Kobayashi, Hideki Ishida, Toshio Takagi
- Hiroki Ishihara, Toshio TakagiEditorial Comment on Disease-free survival as a predictor of overall survival in localized renal cell carcinoma following initial nephrectomy: A retrospective analysis of Surveillance, Epidemiology and End Results-Medicare data. International journal of urology : official journal of the Japanese Urological Association 30 (3) (2023)
- Hiroki Ishihara, Yuki Nemoto, Kazutaka Nakamura, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Kazunari Tanabe, Tsunenori Kondo, Toshio Takagi
- Hiroki Ishihara, Yuki Nemoto, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Yasunobu Hashimoto, Toshio Takagi, Hideki Ishida, Tsunenori Kondo, Kazunari Tanabe
- Hiroki Ishihara, Hironori Fukuda, Kazuhiko Yoshida, Yasunobu Hashimoto, Tsunenori Kondo, Toshio Takagi
- Hiroki Ishihara, Tsunenori Kondo, Toshio TakagiEditorial Comment from Dr Ishihara et al. to Nomogram for predicting survival of renal cell carcinoma with tumor thrombus based on perioperative clinicopathological factors from a Chinese high-volume center. International journal of urology : official journal of the Japanese Urological Association 29 (9) (2022)
- Maki Yoshino, Hiroki Ishihara, Yuki Nemoto, Kazutaka Nakamura, Koichi Nishimura, Hidekazu Tachibana, Hironori Fukuda, Daisuke Toki, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Kazunari Tanabe, Tsunenori Kondo, Toshio Takagi
- Yuki Nemoto, Hiroki Ishihara, Kazutaka Nakamura, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Kazunari Tanabe, Tsunenori Kondo, Toshio Takagi
- Hiroki Ishihara, Yuki Nemoto, Kazutaka Nakamura, Takashi Ikeda, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Toshio Takagi, Hideki Ishida, Tsunenori Kondo, Kazunari Tanabe
- Hiroki Ishihara, Hironori Fukuda, Hidekazu Tachibana, Kazuhiko Yoshida, Hirohito Kobayashi, Toshio Takagi, Junpei Iizuka, Hideki Ishida, Yoji Nagashima, Tsunenori Kondo, Kazunari Tanabe
- Hiroki Ishihara, Hidekazu Tachibana, Toshio Takagi, Kazuhiko Yoshida, Tsunenori Kondo, Kazunari Tanabe
- Yuki Nemoto, Hiroki Ishihara, Kazutaka Nakamura, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Kazunari Tanabe, Tsunenori Kondo, Toshio Takagi
- Hiroki Ishihara, Toshio Takagi, Kazuhiko Yoshida, Yasunobu Hashimoto, Tsunenori Kondo, Kazunari TanabeTumor response in primary kidney lesions and metastatic lesions in nivolumab plus ipilimumab therapy for advanced renal cell carcinoma without prior nephrectomy: Preliminary results of a multi-institutional study. International journal of urology : official journal of the Japanese Urological Association 28 (10) (2021)
- Yudai Ishiyama, Tsunenori Kondo, Hiroki Ishihara, Kazuhiko Yoshida, Junpei Iizuka, Kazunari Tanabe, Toshio Takagi
- Hiroki Ishihara, Tsunenori Kondo, Kazutaka Nakamura, Yuki Nemoto, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Kazunari Tanabe, Toshio Takagi
- Hiroki Ishihara, Toshio Takagi, Tsunenori Kondo, Hironori Fukuda, Kazuhiko Yoshida, Kazunari Tanabe
- Hiroki Ishihara, Hidekazu Tachibana, Toshio Takagi, Tsunenori Kondo, Hironori Fukuda, Kazuhiko Yoshida, Junpei Iizuka, Hirohito Kobayashi, Masayoshi Okumi, Hideki Ishida, Kazunari Tanabe
- Hiroki Ishihara, Satoshi Yamashita, Yu-Yu Liu, Naoko Hattori, Omar El-Omar, Takashi Ikeda, Hironori Fukuda, Kazuhiko Yoshida, Toshio Takagi, Sekiko Taneda, Tsunenori Kondo, Yoji Nagashima, Kazunari Tanabe, Toshikazu Ushijima
- Hiroki Ishihara, Tsunenori Kondo, Toshio Takagi, Kazuhiko Yoshida, Masayoshi Okumi, Kazunari Tanabe
- Hiroki Ishihara, Toshio Takagi, Tsunenori Kondo, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Junpei Iizuka, Hirohito Kobayashi, Masayoshi Okumi, Hideki Ishida, Kazunari Tanabe
- Hiroki Ishihara, Toshio Takagi, Tsunenori Kondo, Hironori Fukuda, Kazuhiko Yoshida, Junpei Iizuka, Kazunari Tanabe
- Hiroki Ishihara, Toshio Takagi, Tsunenori Kondo, Kazuhiko Yoshida, Masayoshi Okumi, Kazunari Tanabe
- Hiroki Ishihara, Toshio Takagi, Tsunenori Kondo, Hironori Fukuda, Hidekazu Tachibana, Kazuhiko Yoshida, Junpei Iizuka, Hirohito Kobayashi, Masayoshi Okumi, Hideki Ishida, Kazunari Tanabe
- Hiroki Ishihara, Toshio Takagi, Tsunenori Kondo, Hidekazu Tachibana, Kazuhiko Yoshida, Kenji Omae, Junpei Iizuka, Hirohito Kobayashi, Kazunari Tanabe
- Kana Iwamoto, Hiroki Ishihara, Toshio Takagi, Tsunenori Kondo, Kazuhiko Yoshida, Junpei Iizuka, Kazunari Tanabe
- Hiroki Ishihara, Tsunenori Kondo, Kazunari TanabeEvaluation of First-Line Sorafenib Treatment for Metastatic Renal Cell Carcinoma in Kidney Transplant Patients: A Single-Center Experience With Four Cases. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 21 (4) (2017)
- Hiroki Ishihara, Masayoshi Okumi, Kazunari Tanabe, null nullPrimary Central Nervous System Post-Transplant Lymphoproliferative Disorder Following Kidney Transplantation: A Multi-Institution Study in Japan Over 30 years. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 21 (5) (2017)